A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Clinical trial NCT05094804 · UNKNOWN

Trial details

NCT number: NCT05094804
Sponsor: OncoResponse, Inc.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Cancer Tumor, Solid Malignant Neoplasm Metastatic Cancer Advanced Solid Tumor Non Small Cell Lung Cancer Melanoma Head and Neck Squamous Cell Carcinoma Leiomyosarcoma Liposarcoma

Start date: 2021-09-09
Primary completion: 2024-04-15
Enrollment: 172

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.